Lineage Cell Therapeutics, a clinical-stage biotech developing allogeneic cell therapies for unmet medical needs, has announced that Jill Howe will join as the company’s Chief Financial Officer, effective November 14.
Howe brings more than 20 years of significant strategic, financial, and operational experience to Lineage, with an emphasis on capital strategy, corporate finance, treasury management, global infrastructure, and operational excellence. She has successfully built biotechnology organizations and implemented operational infrastructures alongside the execution of over $1.66bn of capital raising transactions.
Most recently, Howe was Chief Financial Officer of DTx Pharma, and prior to that, was Vice President of Finance and Treasurer at Gossamer Bio, serving an integral role in the company’s initial public offering (IPO) and concurrent listing on the Nasdaq Global Select Market, various follow-on and debt deals, and overseeing all aspects of finance and accounting operations globally. She also served as a Board member of all Irish and Luxembourg subsidiaries of Gossamer Bio.
From 2016 through 2017 she served as Controller & Director of Finance at Amplyx Pharmaceuticals, Inc., a company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems, which was subsequently acquired by Pfizer.
From 2013 to 2016 she served as Controller & Director of Finance at Receptos, which was subsequently acquired by Celgene for more than $7bn.
From 2006 to 2013 she worked in various accounting roles, leading up to Director of Finance, at Somaxon Pharmaceuticals, which was acquired by Pernix in 2012.
Howe earned her Bachelor of Arts in Accounting from San Diego State University and serves on the Board of Directors of various non-profit, private and public biotechnology companies. In 2022, she won the 2022 CFO of the Year Award in the small business category from the San Diego Business Journal.